<DOC>
	<DOCNO>NCT01156311</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability BG00012 ( dimethyl fumarate ) administer combination interferon b ( IFNß ) glatiramer acetate ( GA ) participants relapsing-remitting multiple sclerosis ( RRMS ) .</brief_summary>
	<brief_title>BG00012 Phase 2 Combination Study Participants With Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>Key Must confirm diagnosis relapsingremitting multiple sclerosis ( RRMS ) accord McDonald criterion # 14 ( Polman et al , 2005 [ Appendix I ] ) , prior brain magnetic resonance imaging ( MRI ) demonstrate lesion ( ) consistent multiple sclerosis ( MS ) point time . Must Expanded Disability Status Scale ( EDSS ) 0.0 5.0 , inclusive . Must take dose prescribe IFNβ ( either Avonex , Betaseron , Rebif ) GA least 12 month consecutively time enrollment remain treatment duration study . Participants receive Rebif must prescribe 44 μg subcutaneous injection three time per week . Key Primary progressive , secondary progressive , progressive relapsing MS ( define Polman et al . 2005 ) . Other chronic disease immune system , malignancy , acute urologic , pulmonary disease . Pregnant nursing woman . Participation within 6 month prior study enrollment drug , biologic , device study . NOTE : Other protocoldefined Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>BG00012</keyword>
	<keyword>MS</keyword>
	<keyword>RRMS</keyword>
</DOC>